Silverback Therapeutics, Inc. SBTX
Set alert
5.87 +5.87 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 211.66M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.76
- Beta
- 0.00
- Short ratio
- 5.20
- Inst. own
- 78.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2022
- 50-d avg
- 5.39
- 200-d avg
- 4.37
- 1y target
- 5.00
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00
Recommendation trend
- 1 month ago 2
- 2 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.34 | -0.37 – -0.32 | -0.67 | +49.3% | 0 | 0.0% | 2 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.70 | 0.0% | 0 | 0.0% | 0 |
| Current year | -1.92 | -2.07 – -1.78 | -2.56 | +25.0% | 0 | 0.0% | 2 |
| Next year | -2.13 | -2.17 – -2.09 | -1.92 | -10.9% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 4, 2022 | Goldman Sachs | Downgrade | Buy | Neutral |
| Apr 1, 2022 | JonesTrading | Downgrade | Buy | Hold |
| Apr 1, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Apr 1, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Apr 1, 2022 | Stifel | Downgrade | Buy | Hold |
| Nov 12, 2021 | SVB Leerink | Maintained | — | Outperform |
| Aug 16, 2021 | SVB Leerink | Maintained | — | Outperform |
| May 27, 2021 | JonesTrading | Initiated | — | Buy |
| May 17, 2021 | SVB Leerink | Maintained | — | Outperform |
| Apr 6, 2021 | SVB Leerink | Maintained | — | Outperform |
| Mar 30, 2021 | Stifel | Maintained | — | Buy |
| Dec 29, 2020 | SVB Leerink | Initiated | — | Outperform |
| Dec 29, 2020 | Stifel | Initiated | — | Buy |
| Dec 29, 2020 | HC Wainwright & Co. | Initiated | — | Buy |